share_log

SciSparc | CORRESP: CORRESP

SciSparc | CORRESP: CORRESP

SciSparc | CORRESP:信函
美股SEC公告 ·  2024/06/18 00:42

Moomoo AI 已提取核心訊息

SciSparc Ltd., a biotechnology company, has submitted Post-Effective Amendment No. 2 to its Registration Statement on Form F-1 to the U.S. Securities and Exchange Commission (SEC) on June 17, 2024. This submission is in response to the SEC's comment letter dated May 16, 2024, regarding the company's initial Post-Effective Amendment No. 1 filed on May 2, 2024. SciSparc has addressed the SEC's comments by revising its prospectus to clarify whether the combined entity, following its merger with AutoMax, will continue the business of SciSparc, AutoMax, or both. Additionally, the company has updated the 'Use of Proceeds' section to specify how the proceeds from the SEPA will be utilized, whether for SciSparc's or AutoMax's operations. SciSparc has also provided a comprehensive discussion of AutoMax's business operations as requested by the SEC. The company acknowledges its responsibility for the accuracy and adequacy of its disclosures.
SciSparc Ltd., a biotechnology company, has submitted Post-Effective Amendment No. 2 to its Registration Statement on Form F-1 to the U.S. Securities and Exchange Commission (SEC) on June 17, 2024. This submission is in response to the SEC's comment letter dated May 16, 2024, regarding the company's initial Post-Effective Amendment No. 1 filed on May 2, 2024. SciSparc has addressed the SEC's comments by revising its prospectus to clarify whether the combined entity, following its merger with AutoMax, will continue the business of SciSparc, AutoMax, or both. Additionally, the company has updated the 'Use of Proceeds' section to specify how the proceeds from the SEPA will be utilized, whether for SciSparc's or AutoMax's operations. SciSparc has also provided a comprehensive discussion of AutoMax's business operations as requested by the SEC. The company acknowledges its responsibility for the accuracy and adequacy of its disclosures.
2024年6月17日,生物技術公司SciSparc有限公司向美國證券交易委員會(SEC)提交了《E表格》的註冊聲明書第1號後生效修正案第2號。本次提交是針對SEC於2024年5月16日發出的評論函所做的回應,該評論函涉及公司於2024年5月2日提交的後生效修正案第1號。SciSparc通過修訂招股說明書來回應SEC的評論,澄清合併後的公司將繼續SciSparc的業務、AutoMax的業務,還是兩者兼而有之的業務。此外,公司還更新了“募集資金的用途”部分,以說明SEPA的收益將用於SciSparc或AutoMax的運營。SciSparc還提供了SEC要求的AutoMax業務運營的全面討論。公司承認其對信息披露的準確性和充分性負責。
2024年6月17日,生物技術公司SciSparc有限公司向美國證券交易委員會(SEC)提交了《E表格》的註冊聲明書第1號後生效修正案第2號。本次提交是針對SEC於2024年5月16日發出的評論函所做的回應,該評論函涉及公司於2024年5月2日提交的後生效修正案第1號。SciSparc通過修訂招股說明書來回應SEC的評論,澄清合併後的公司將繼續SciSparc的業務、AutoMax的業務,還是兩者兼而有之的業務。此外,公司還更新了“募集資金的用途”部分,以說明SEPA的收益將用於SciSparc或AutoMax的運營。SciSparc還提供了SEC要求的AutoMax業務運營的全面討論。公司承認其對信息披露的準確性和充分性負責。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息